Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 868

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 868
---
, tangible personal property, business records, warranties, and deposits. The purchase price for these assets is $450,000, which will be paid in cash, plus the assumption of certain liabilities associated with the
acquired assets. The Pacira APA stipulates that the assets will be transferred free and clear of all encumbrances. Additionally, the Pacira APA includes provisions for indemnification, confidentiality, and further assurances to facilitate the smooth
transfer and continued operation of the acquired assets. The closing of the transaction is subject to customary closing conditions and is expected to occur in the first quarter of 2025. In February 2025, the Company received cash of $450,000
pursuant to the asset purchase agreement.

HCRX Asset Sale

The license agreements with each of Merck & Co., Inc., Genentech, Inc. and FAIR Therapeutics, B.V., (collectively, the “Partnered Programs”)
were sold to HCRX pursuant to the HCRX Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the HCRX Agreement, Kineta will sell to HCRX all of Kineta’s rights, title and interest in and to the
Partnered Programs, for a purchase price of $1.00 in cash and the right to receive 72.5% or 45%, as applicable, of any milestone or royalty payments payable to Kineta pursuant to the Partnered Programs for a period not to exceed six years.

F-130

KINETA, INC.

Notes to Consolidated Financial Statements

GigaGen

VISTA Agreement Third Amendment

On January 29, 2025,
Kineta and GigaGen entered into the Third Amendment to Option and License Agreement (the “Third Amendment to VISTA Agreement”) to, among other things, amend the development and regulatory milestone payments under the VISTA Agreement.
Pursuant to the Third Amendment to VISTA Agreement, GigaGen is eligible to receive approximately $20.3 million in development and regulatory milestone payments, including payments previously paid by Kineta.

CD27 Asset Transfer

GigaGen and Kineta entered into a
Termination and Mutual Release Agreement, effective January 29, 2025, to terminate their existing CD27 Agreement. The termination is mutually agreed upon and is not due to any fault or breach by either party. GigaGen waived all accrued fees
amounting to $180,000 and any future payments from Kineta.